FY26 EBITDA Margin: ~32%
Management expects EBITDA margins to end at approximately 32% for FY26, down from earlier guidance of 33-34%, due to pre-operative expenses of new centers.
SURAKSHA / guidance tracker
Keep management guidance in view.
Suraksha Diagnostic · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
FY27 Q3: Margin Recovery Expected
As new centers mature and economies of scale set in, management expects margins to revert to higher levels from Q3 FY27 onwards.
Genomics Annual Run Rate: ₹4+ Crore by FY27
Management targets genomics segment to reach ₹4+ crore annual run rate in FY27, growing in multiples rather than gradually, entering cancer and preventive genomics.
100 Centers by FY28
Company targets 100 centers by FY28, planning 12-15 center additions annually (5 hub + 10 small format), with expansion into Northeast states and Bihar.